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Properties of a flavonol-based photoCORM in
aqueous buffered solutions: influence of metal
ions, surfactants and proteins on visible light-
induced CO release†
Marina Popova,a Tatiana Soboleva,a Atta M. Arifb and Lisa M. Berreau *a
The properties of the extended flavonol 3-hydroxy-2-phenyl-benzo[g]chromen-4-one (2a) in
DMSO : aqueous buffer solutions at pH ¼ 7.4, including in the presence of metal ions, surfactants and
serum albumin proteins, have been examined. Absorption and emission spectral studies of 2a in 1 : 1
DMSO : PBS buffer (pH ¼ 7.4) indicate that a mixture of neutral and anionic forms of the flavonol are
present. Notably, in 1 : 1 DMSO : TRIS buffer (pH ¼ 7.4) only the neutral form of the flavonol is present.
These results indicate that the nature of the buffer influences the acid/base equilibrium properties of 2a.
Introduction of a Zn(II) complex of 2a to a 1 : 1 DMSO : aqueous buffer (TRIS or PBS, pH ¼ 7.4) solution
produces absorption and emission spectral features consistent with the presence of a mixture of neutral
2a along with Zn(II)-coordinated or free 2a. The nature of the anionic species present depends on the
buffer composition. PBS buffered solutions (pH ¼ 7.4) containing the surfactants CTAB or SDS enable 2a
to be solubilized at a much lower percentage of DMSO (3.3–4.0%). Solutions containing the cationic
surfactant CTAB include a mixture of 2a and 2a whereas only the neutral flavonol is present in SDS-
containing buffered solution. Compound 2a is also solubilized in TRIS buffer solutions at low
cocentrations of DMSO (3.3%, pH ¼ 7.4) in the presence of serum albumin proteins. Stern–Volmer
analysis of the quenching of the inherent protein fluorescence indicates static binding of 2a to the
proteins. The binding constant for this interaction is lower than that found for naturally-occurring
flavonols (quercetin or morin) or 3-hydroxyflavone. Compound 2a binds to Site I of bovine and human
serum albumin proteins as indicated by competition studies with warfarin and ibuprofen, as well as by
docking investigations. The quantum yield for CO release from 2a (lirr ¼ 419 nm) under aqueous
conditions ranges from 0.0006(3) when the compound is bound to bovine serum albumin to 0.017(1)
when present as a zinc complex in a 1 : 1 DMSO : H2O solution. Overall, the results of these studies
demonstrate that 2a is a predictable visible light-induced CO release compound under a variety of
aqueous conditions, including in the presence of proteins.
Introduction
Carbonmonoxide (CO) is generated in humans via the oxidative
degradation of heme, which is catalyzed by heme oxygenase
enzymes.1 The discovery of benecial health effects associated
with the delivery of small amounts of CO, including anti-
inammatory, anti-apoptotic, and anti-proliferative effects, as
well as the promotion of vasodilation and protection of tissues
against reperfusion injury, has led to investigations of the
possible use of CO as a therapeutic.2–8 Several clinical trials are
currently in progress involving the use of inhaled carbon
monoxide.9–14 A challenge in using inhaled CO as a therapeutic
is that it does not enable the delivery of controlled amounts of
CO to specic targets and diffusion into tissues is unpredict-
able. As an approach toward introducing controlled amounts of
CO, several research labs have worked on the development of
CO-releasing molecules (CORMs).15,16 The most widely investi-
gated CORMs to date are metal carbonyl complexes,17 with
CORM-1 and CORM-3 (Fig. 1(top)) having been employed in
a variety of biological investigations. Metal carbonyl-based
CORMs release CO either spontaneously via ligand exchange,
or via triggering with light (photoCORMs),18–25 enzyme
activity,26–29 or magnetic heating30–32 (Fig. 1). A drawback of the
use of metal carbonyl complexes as CORMs is the possible (or
perceived) toxicity of the residual low-valent metal fragment
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remaining following CO release. Additionally, little is currently
known in terms of the reactivity of metal carbonyl-based
CORMs with other biomolecules. It was only aer CORM-3
had been used in a several biological studies that the active
form for CO-release in vivo was determined to likely be
a protein-bound Ru(CO)2 species.33,34 In general, although many
metal carbonyl species have been demonstrated to be CORMs
and to enable CO release both in vitro and in cellular environ-
ments, very few have been studied with regard to their inter-
actions with biological molecules, such as proteins.35,36 These
interactions could dramatically affect the CO-release reactivity.
Metal-free CORMs37,38 and photoCORMs39–42 (Fig. 2) have
recently emerged as alternatives to metal carbonyl-based CO-
releasing molecules. Of the structural frameworks reported
thus far for metal-free photoCORMs, the BODIPY and extended
avonol motifs (Fig. 2) are notable in that they can be tuned to
enable the use of low energy visible light (>575 nm) to induce
CO release, which is important for use in biological environ-
ments. The CO release unit in 1a/1b is a carboxyl moiety
whereas the extended avonol motif in 2a–d contains a pyrone
ring that is similar to naturally occurring avonols (e.g., quer-
cetin), which are known to undergo enzyme-catalyzed CO
release.43 The visible light-induced CO release reaction
involving 1a or 1b proceeds in high yield (87–92%) only under
anaerobic conditions, with the yield of CO under aerobic
conditions dropping to 42–44%.39 Visible light-induced carbon
monoxide release from 2a–c requires the presence of O2 for
a quantitative, dioxygenase-type reaction to produce an O-ben-
zoylsalicylic acid product (3a, Scheme 1). Complex 2d exhibits
both aerobic and anaerobic visible light-induced quantitative
CO release reactivity.42
Development of an understanding of the properties of metal-
free CO-releasing photoCORM frameworks in aqueous buffered
solutions and in the presence of biomolecules is essential
toward the further development of these motifs as potential
biological tools and therapeutics. Klán and coworkers have re-
ported that at pH ¼ 7.4 in PBS buffer, 1a and 1b exist as mon-
oanions, with a deprotonated carboxyl group (pKa¼ 3.0 0.2).39
Under anaerobic conditions in PBS (pH ¼ 7.4) visible light-
induced CO release occurs from 1a and 1b with quantum
yields of 1.2(4)  104 and 1.2(4)  105, respectively. It is
currently unknown how a biological environment, including the
presence of proteins, will affect these values. The organic
products in these CO release reactions also remain only
partially characterized.
We have previously reported the visible light-induced CO
release reactivity of 2a–d42 and zinc complexes of these avonols
in organic solvent (acetonitrile).44 All exhibit quantitative CO
release under aerobic conditions. The quantum yields for these
reactions are signicantly affected by the presence of a neutral
versus anionic form of the avonol. Specically, for 2a the
quantum yield for CO release in CH3CN is 0.007(3) whereas for
zinc complex of 2a it is 0.651(2), a >90-fold increase.42,44
Experimental and computational studies of 3-hydroxyavone (3-
HH) indicate that the pKa for this compound is 8.5 in
aqueous solution.45 In this contribution, we examine the
Fig. 1 Examples of metal carbonyl-based CORMs.17,20,28,30
Fig. 2 Metal-free CORMs and photoCORMs reported to date.36–41
Scheme 1 Visible light-induced CO release reaction of 2a.
































































































aqueous solution chemistry of 2a at pH ¼ 7.4 in buffered
solutions that includemetal ions, surfactants or serum albumin
proteins. Our results indicate that the components of the
aqueous buffered environment affect the 2a/2a equilibrium
(Scheme 2) and modestly inuence the quantum yield for CO
release. Our studies reveal that 2a is a reliable CO release motif
under a variety of aqueous buffered conditions. Combined with
its straight-forward preparation, moderate toxicity, and the non-
toxic nature of the O-benzoylsalicylate product (3a) remaining
following CO release, 2a exhibits many features desirable in




Compound 2a was prepared according to the literature proce-
dure.42 All reagents were used as received unless otherwise noted.
Cetrimonium bromide (CTAB) was purchased from TCI. Sodium
dodecylsulfate (SDS) was purchased from Acros Organics. Bovine
serum albumin (BSA, heat shock fraction) and human serum
albumin (HAS, lyophilized powder,$97%) were purchased from
Sigma Aldrich. Warfarin was purchased from Cayman Chemicals
Company. Ibuprofen was purchased from Alfa Aesar. Double-
distilled or distilled water was used in all experiments.
Instrumentation
1H and 13C NMR spectra were collected using a Bruker Avance
III HD Ascend-500 spectrometer. UV-vis spectra were recorded
at ambient temperature using a Cary 50Bio or a Hewlett–Pack-
ard 8453A diode array spectrophotometer. Fluorescence emis-
sion spectra were recorded using a Shimadzu RF-530XPC
spectrometer using 1.0 cm quartz cells. The excitation and
emission slit widths were set at 3.0 nm. IR spectra were
collected using a Shimadzu FTIR-8400 spectrometer. Mass
spectral data were collected at the Mass Spectrometry Facility,
University of California, Riverside. Elemental analyses were
performed by Robertson Microlit Laboratory, Ledgewood, NJ. A
Rayonet photoreactor equipped with RPR-419 lamps was used
for all photochemical reactions. Quantum yields were deter-
mined as previously described using potassium ferrioxalate as
a standard to measure photon ux.46–48
[(bpy)Zn(2a)]ClO4 (4)
Zn(ClO4)2$6H2O (50 mg, 0.13 mmol) dissolved in 1 ml of
methanol was added to 2,20-bipyridine (21 mg, 0.13 mmol) in
1 ml of methanol. The resulting mixture was added to
a mixture of 2a (39 mg, 0.13 mmol) and Me4NOH$5H2O
(24 mg, 0.13 mmol) in methanol (2 mL). The reaction mixture
was stirred at room temperature for 3 hours. The resulting
solution was divided into three parts and solvent was
removed under reduced pressure. The remaining residue was
dissolved in CH2Cl2, the solution was ltered through Celite
plug, and the solvent was removed under vacuum. The
product was recrystallized from ACN/Et2O, which resulted in
the deposition of X-ray quality crystals (45%). IR (KBr, cm1)
1100 (nClO4), 623 (nClO4); UV-vis (DMSO, nm) (3, M
1 cm1) 378
(3100), 479 (15 100); ESI/APCI MS (positive ion): m/z calcu-
lated for C29H19N2O3Zn: 507.0722 [M–ClO4]
+, found:
507.0699; elemental analysis calc. for C29H19N2O7-
ClZn$0.5H2O: C, 56.42%; H, 3.27%; N, 4.61%. Found: C
56.31; H, 2.85; N, 4.60.
X-ray crystallography
A translucent light orange plate-like crystal of 4 of approximate
dimensions 0.140 mm  0.168 mm  0.392 mm was mounted
using a viscous oil. Data were collected using a Nonius Kappa
CCD diffractometer (Mo Ka, l ¼ 0.71073 Å). A total of 2079
frames were collected and subsequently integrated with the
Bruker SAINT soware package using a narrow-frame algo-
rithm. The integration of the data using a monoclinic unit cell
yielded a total of 51 427 reections to a maximum q angle of
30.03 (0.71 Å resolution), of which 7184 were independent
(average redundancy 7.159, completeness ¼ 99.8%, Rint ¼
2.75%, Rsig ¼ 1.73%) and 6280 (87.42%) were greater than
2s(F2). The nal cell constants of a¼ 8.2518(2) Å, b¼ 14.8377(4)
Å, c ¼ 20.0844(6) Å, b ¼ 92.219(2), volume ¼ 2457.24(12) Å3, are
based upon the renement of the XYZ-centroids of reections
above 20 s(I). Data were corrected for absorption effects using
the multi-scan method (SADABS). The calculated minimum and
maximum transmission coefficients (based on crystal size) are
0.6600 and 0.8540, respectively.
The structure of 4 was solved and rened using the Bruker
SHELXTL Soware Package, using the space group P21n with Z
¼ 4 for the formula unit C29H19ClN2O7Zn. The nal anisotropic
full-matrix least-squares renement on F2 with 370 variables
converged at R1 ¼ 3.18%, for the observed data and wR2 ¼
8.97%. The goodness-of-t was 1.062. The largest peak in the
nal difference electron density was 1.263 e Å3 with an RMS
deviation of 0.066 e Å3. On the basis of the nal model, the
calculated density was 1.644 g cm3 and F(000), 1240 e. The
structure was deposited in the Cambridge Crystallographic
Database (CCDC 1523782).
Buffer preparation
TRIS (0.05 M) at pH¼ 7.4 was prepared using amixture of TRIS–
HCl and TRIS-base. Sodium chloride (0.1 M) was added to
maintain ionic strength. Phosphate buffered saline (PBS) was
prepared containing 140 mM NaCl, 3 mM KCl, and 10 mM
phosphate and was adjusted to pH ¼ 7.4 using aqueous HCl.
Scheme 2 Acid/base equilibrium of 2a.
































































































Solution studies of 2a in the presence of CTAB and SDS
Experiments were performed in PBS : DMSO (96.7 : 3.3% v:v,
pH ¼ 7.4). The absorption and emission properties of 2a were
evaluated in the presence of varying amounts of CTAB or SDS.
Solution studies of 2a in the presence of bovine or human
serum albumin
Emission spectra of solutions of 2a (1.4  106 M) in
TRIS : DMSO (96 : 4% v:v, pH ¼ 7.4) were collected from 410 to
800 nm in the presence of varying amounts of bovine or human
serum albumin (1 : 0 to 1 : 40). The excitation wavelength was
408 nm, which corresponds to the absorption maximum of 2a.
Serum albumin binding studies
Binding studies of 2a to bovine or human serum albumin were
performed using tryptophan uorescence quenching experi-
ments in TRIS : DMSO (96 : 4% v:v, pH ¼ 7.4). The excitation
wavelengths used for BSA and HSA were 282 and 285 nm,
respectively. Emission spectra were recorded from 300 to
600 nm. The maximum emission intensities at 340 nm were
used to calculate binding constants and to determine the
number of binding sites.
Molecular docking
Studies were performed using AutoDock Vina 1.1.2 soware.49
The crystal structure of BSA was downloaded from the RSCB
Protein Data Bank (PDB entry code 3V03). The X-ray crystallo-
graphically determined structure of 2a42 was converted to pdbqt
format with MGLTools for use as an input le for AutoDock
Vina. A structure of the O-benzoylsalicylic acid CO release
product 3a was energy minimized using Chem 3D (MM2 force
eld) and saved in pdbqt format using MGLTools for input into
AutoDock Vina. A semi-exible docking procedure was per-
formed wherein BSA was kept rigid and stationary and was
assigned with polar hydrogen atoms. Compound 2a with two
rotatable bonds and 3a with ve rotatable bonds were allowed
to be exible as they were docked into the protein. A grid box
with dimensions 60  68  68 points with the spacing of 1.0 Å
was used to accommodate the ligands to move freely during
each docking run. The lowest energy docked conformations
identied for 2a and 3a with BSA were visualized using Pymol.
Independent synthesis of 3-(benzoyloxy)-2-naphthoic acid (3a)
3-Hydroxy-2-naphthoic acid, (0.50 g, 2.7 mmol) in 3 ml dry
diethyl ether was mixed with pyridine (0.58 ml, 7.2 mmol). The
resulting mixture was cooled in an ice bath and a solution of
benzoyl chloride (0.31 ml, 2.7 mmol) in diethyl ether (2 mL) was
added. The reaction mixture was warmed to room temperature
and then stirred for 1 hour. H2O (10 ml) was then added. The
solution was acidied with 2 M HCl until pH 4 was obtained.
The mixed aqueous/organic mixture was then extracted using
chloroform (3  15 ml). The organic fractions were combined,
dried over Na2SO4, the solution was ltered, and the solvent was
removed from the ltrate under reduced pressure. The product
was puried by column chromatography using hexanes : ethyl
acetate (1 : 1) as the eluent. 3-(Benzoyloxy)-2-naphthoic acid (3a)
was obtained as colorless needles (0.20 g, 25%) following
removal of solvent. The 1H NMR features of the product in
CD3CN matched with those previously reported.42
1H NMR (500
MHz, CD3OD) d ppm 8.66 (s, 1H), 8.23 (d, J¼ 9 Hz, 2H), 8.05 (d, J
¼ 9.5 Hz, 1H), 7.93 (d, J ¼ 9 Hz, 1H), 7.73 (s, 1H), 7.69 (t, J ¼
7.5 Hz, 1H), 7.65 (t, J ¼ 7.5 Hz, 1H), 7.56 (m, 3H); 13C{1H} NMR
(125 MHz, CD3OD) d 169.4, 169.0, 149.9, 138.5, 136.2, 136.1,
133.6, 132.7, 132.6, 131.5, 131.4, 131.1, 129.8, 129.3, 125.9,
123.6 ppm (16 signals expected and observed); IR (KBr, cm1)
1743 (nC]O); ESI/APCI MS (negative ion): m/z calculated for
C18H12O4: 291.0657, found: 291.0674. m.p. 173–175 C.
Results
Properties of 2a in 1 : 1 DMSO : aqueous buffer at pH ¼ 7.4
When dissolved in 1 : 1 DMSO : Tris buffer at pH 7.4,
compound 2a exhibits features consistent with the presence of
the neutral avonol (Fig. 3). Specically, an absorption band
with a maximum at approximately 409 nm is similar to that
observed for the compound in CH3CN and 1 : 1 DMSO : H2O.42
When 2a is dissolved in 1 : 1 DMSO : PBS buffer at pH 7.4
(Fig. 3), an absorption feature at 480 nm is also present. This
red-shied band is consistent with the presence of the a-
vonolato anion (2a) based on comparison to spectroscopic
features of Zn(II) complexes of 2a.44 The same 480 nm band is
present when 2a is dissolved in 1 : 1 DMSO : H2O to which two
equivalents of sodium hydroxide has been added (Fig. S1(a)†).
Fluorescence spectra (lex ¼ 410 and 480 nm) of 1 : 1
DMSO : buffer solutions (pH ¼ 7.4) of 2a provide additional
evidence for the presence of neutral and anionic forms of 2a
under various conditions. When excited at 410 nm, solutions of
2a in 1 : 1 DMSO : H2O, DMSO : TRIS and 1 : 1 DMSO : PBS at
pH ¼ 7.4 exhibit two emission bands at 475 and 580 nm
(Fig. 4), respectively. These emissions are from the normal (N*)
and tautomeric (T*) excited state forms of 2a.50 The T* form is
Fig. 3 Absorbance spectra of 2a (0.10 mM) in various solution envi-
ronments. The 480 nm absorption feature present in 1 : 1
DMSO : PBS at pH 7.4 is associated with the presence of 2a.
































































































the result of excited state proton transfer (ESPT) within the
avonol and formation of the pyrillium ion (Fig. 4). The inten-
sity of the T* emission is lower than that exhibited by 2a in
organic solvent (CH3CN) due to the availability of additional
non-radiative pathways in the hydrogen bonding aqueous
solutions which results in quenching of the excited state.51 The
emission maximum in aqueous environments is also slightly
blue-shied relative to the spectrum of 2a in CH3CN. Excitation
of the same solutions at 480 nm produced an emission at
603 nm in the solution of 2a in 1 : 1 DMSO : PBS buffer. A 1 : 1
DMSO : H2O solution containing two equivalents of sodium
hydroxide gives a similar emission feature (Fig. S1(c)†)
providing evidence that this emission is associated with 2a.
Zinc complex
To gain insight into the properties of 2a in aqueous buffer in
the presence of a divalent metal ion, we have prepared and
characterized [(bpy)Zn(2a)]ClO4 (4) and performed spectro-
scopic studies of this complex. In the solid state, 4 exhibits
a binuclear structure (Fig. 6(a)) with the deprotonated oxygen
atom of each avonolato ligand bridging between two zinc
centers. This coordination motif is similar to that found in
[(bpy)Zn(3-H)]ClO4 (3-H ¼ 3-hydroxyavonolato anion).52 ESI
APCI mass spectral studies of 4 in wet CH3CN (Fig. S2†) indicate
that the mononuclear [(bpy)Zn(2a)]+ ion is present indicating
breakup of the dimer in solution. Additionally, species resulting
from ligand exchange (e.g., [(bpy)2Zn(ClO4)]
+ and [(bpy)2Zn]
2+)
and ligand loss (e.g., [bpyH]+ and [2a] H+) are evident in the
mass spectrum. The UV-vis spectrum of 4 in dry CH3CN, and
1 : 1 DMSO : TRIS and 1 : 1 DMSO : PBS at pH ¼ 7.4, are shown
in Fig. 6(b). The DMSO : buffer solutions show features
consistent with the presence of neutral and anionic forms of 2a.
The emission spectra of 4 (lex ¼ 410 nm; Fig. 6(c)) in 1 : 1
DMSO : TRIS and 1 : 1 DMSO : PBS at pH ¼ 7.4 conrm the
presence of the neutral avonol. Excitation at 480 nm (Fig. 6(d))
produces an emission feature at 554 nm in 1 : 1 DMSO : TRIS
and 603 nm in 1 : 1 DMSO : PBS. The differences in these
spectra are indicative of the presence of zinc-coordinated 2a
and free 2a anion, respectively. The attribution of the emission
at 563 nm to Zn(II) coordinated 2a is made on the basis of
prior studies.44 These results indicate that the zinc ion stays
associated with the 2a anion in 1 : 1 DMSO : TRIS at pH ¼ 7.4,
but is displaced from the zinc center in 1 : 1 DMSO : PBS at the
same pH.
Effects of surfactants
The avonol 2a exhibits low solubility in PBS buffer in the
presence of low amounts of DMSO (3%). This is evident in the
lack of a avonol emission feature of a solution of this
composition and observed precipitation. However, in 1 : 1
DMSO : buffer, 2a is soluble. In order to minimize the amount
of DMSO present and gain insight into how the solubility of 2a
may be impacted by interactions with other biomolecules or
charged species, we have investigated the solution spectro-
scopic properties of 2a in the presence of surfactants. In the
presence of the cationic surfactant CTAB (centrimonium
bromide), compound 2a exhibits absorption and emission
spectra consistent with the presence of a mixture of 2a and 2a
(Fig. 7). The emission features associated with these species
increase in intensity with increasing CTAB concentration
(Fig. 7(b) and (c)), which is similar to studies involving 3-
hydroxyavone.53
Fig. 4 Emission spectra (lex ¼ 410 nm) of solutions of 2a (0.10 mM).
Fig. 5 Emission spectra (lex ¼ 480 nm) of solutions of 2a (0.10 mM).
The emission feature for 2a at 538 nm in CH3CN is attributed to the
neutral flavonol.
































































































In the presence of sodium dodecyl sulphate (SDS), the
absorption and emission features of 2a are consistent with the
presence of only the neutral form of the avonol (Fig. 8). This is
particularly evident in the lack of an emission feature upon
excitation at 480 nm.
Serum albumins
Several studies of the binding properties of avonols to serum
albumin proteins using uorescence spectroscopy have been
previously reported.54–62 In the case of 2a, we selectively exam-
ined the uorescence properties of both the avonol and the
tryptophan residues of the protein to probe the 2a/albumin
interaction. Addition of aliquots of BSA to the avonol in
TRIS : DMSO (96 : 4% v:v, pH ¼ 7.4) results in a saturatable
increase in the intensity of the avonol T* emission band
(Fig. 9). A bathochromic shi (30 nm) of this emission is
observed. We note that a similar red shi of the tautomer
uorescence band was identied for 3-hydroxyavone (3-HH)
upon binding to BSA.54 Notably, the emission maximum
observed for 2a in the presence of BSA matches that found in
a polar aprotic organic solvent (e.g., CH3CN (Fig. 4)) wherein the
ESIPT process is efficient. This suggests a hydrophobic binding
site for the avonol within the protein environment. As shown
in Fig. 10, addition of 2a to BSA in TRIS : DMSO (96 : 4% v:v, pH
¼ 7.4) results in a decrease of the 340 nm intrinsic emission (lex
¼ 282 nm) associated with the tryptophan residues of the
protein. This quenching suggests that 2a binds in close prox-
imity to the tryptophan residues (positions 134 and 213).
Notably, similar quenching is seen upon titration of human
serum albumin (HSA), which contains a single tryptophan
residue at position 214 in subdomain IIA of the protein
(Fig. S3†). For each protein, the Stern–Volmer equation (eqn (1))
Fig. 7 (a) Absorption spectra of 2a (0.10 mM) in the presence of
various concentrations of CTAB. (b) Emission spectra produced with
lex ¼ 410 nm. (c) Emission spectra produced with lex ¼ 480 nm.
Fig. 8 (a) Absorption spectra of 2a (0.10 mM) in the presence of
various concentrations of SDS. (b) Emission spectra produced with lex
¼ 410 nm. (c) Emission spectra produced with lex ¼ 480 nm.
Fig. 6 (a) Thermal ellipsoid representation (50% ellipsoids) of the
binuclear structure of 4. (b) Absorption spectra of 4 (0.10 mM) in 1 : 1
DMSO : TRIS and 1 : 1 DMSO : PBS at pH ¼ 7.4. (c) Emission spectra
produced with lex ¼ 410 nm. (d) Emission spectra produced with lex ¼
480 nm.
































































































was used to classify the type of uorescence quenching induced
by 2a as static or dynamic.54
F0
F
¼ 1þ kqs0½Q ¼ 1þ Ksv½Q (1)
In this equation, F0 and F are the uorescence intensities in
the absence and presence of the quencher (2a), respectively; kq
is the bimolecular quenching constant, s0 is the lifetime of the
uorophore in the absence of quencher (108 s), [Q] is the
concentration of the quencher and Ksv is the Stern–Volmer
bimolecular quenching constant.54 The Stern–Volmer plot for
the titration of BSA with 2a is shown in Fig. 10(b). As kq (1.1 
1013 M1 s1) is much larger than 2  1010 M1 s1 (the
maximum diffusion collision quenching rate constant of
various quenchers with the biopolymer), it is likely that the
quenching in this case is static in nature.54 The binding
constant Ka and number of binding sites n were calculated from
the modied Stern–Volmer plot (Fig. 10(c)) for the titrations of






¼ log Ka þ n log½Q (2)
where [Q] is [2a]. A plot of log((F0–F)/F0) versus log[Q] yields
log Ka as the intercept and n as the slope (Fig. 10(c)). The
binding constant Ka and binding sites n for 2a with BSA and
HSA are listed in Table 1. Notably, only one equivalent of 2a
binds to BSA and HSA versus two equivalents of the structurally
similar but smaller 3-hydroxyavone (3-HH).54,55 The binding
constant for 2a is 45-fold lower than that of 3-HH and is also
signicantly lower than that of hydroxyl-substituted 3-HH
derivatives that are naturally occurring compounds (e.g., quer-
cetin and morin; Table 1).
Most drug molecules bind to BSA in subdomains IIA and
IIIA. Site I (subdomain IIA) is where the blood thinner drug
warfarin binds whereas Site II (subdomain IIIA) is the location
of ibuprofen binding.63 To gain insight into the binding site of
2a in BSA, displacement studies were performed with warfarin
and ibuprofen. Pre-equilibration of a BSA : warfarin (1 : 1)
mixture for 1 h followed by titration with 2a resulted in the loss
of tryptophan uorescence intensity. The binding constant for
Fig. 9 Emission features of 2a (1.4 mM) upon addition of increasing
amounts of BSA in TRIS : DMSO (96 : 4% v:v, pH¼ 7.4). T¼ 293 K, lex¼
410 nm.
Fig. 10 (a) Fluorescence emission spectra of BSA (1.4 mM) in the
presence of various concentrations of 2a in TRIS/NaCl : DMSO
(96 : 4% v:v, pH ¼ 7.4); T ¼ 298 K, lex ¼ 282 nm. [2a] ¼ 0, 1.4, 2.8, 5.6,
8.4, 11.2, 16.8, and 22.4 mM. (b) Stern–Volmer plot of data for titration
of BSA with 2a. (c) Modified Stern–Volmer plot of data for titration of
BSA with 2a.
Table 1 Binding constants of 2a and 3a with serum albumin proteins






2a-BSA 3.2  103 0.66 This work
2a-BSA (Zn2+) 1.9  102 0.48 This work
[(bpy)Zn(2a)]ClO4 1.0  102 0.39 This work
2a-BSA (Ca2+) 3.2  103 0.71 This work
2a-BSA (Mg2+) 2.5  103 0.69 This work
2a-BSA (warfarin) 2.8  102 0.46 This work
2a-BSA (ibuprofen) 2.5  103 0.67 This work
2a-HSA 3.0  103 0.7 This work
2a-HSA (warfarin) 2.5  103 0.66 This work
2a-HSA (ibuprofen) 3.0  103 0.67 This work
3-HFlH-BSA 1.1–1.3  105 2 54
3-HH-HSA 7.2  105; 2.5  105 2 55
Quercetin-BSA 3.65  107 1.29 56
Quercetin-BSA 1.00  105 0.84 57
Quercetin-BSA 4.85  105 1.19 58
Quercetin-HSA 2.30  104 1.10 58
Morin-HSA 1.13  105 1.06 59
3a-BSA 8.5  107 1.7 This work
3a-BSA (warfarin) 6.7  103 0.9 This work
3a-BSA (ibuprofen) 2.5  105 1.2 This work
BSA-aspirin 5.0  103 64
































































































2a determined from this data (2.8  102 M1; Fig. S4(a)†) is
lower than that observed in the absence of warfarin, suggesting
competition for the binding site. A similar experiment involving
ibuprofen (Fig. S4(b)†) produced almost no change in the
binding constant for 2a, indicating that no binding of this
compound occurs in Site II.
To further probe the binding site of 2a with BSA we per-
formed in silico docking studies using AutoDock Vina.49 Two
different high affinity binding conformations (Fig. 11) were
identied near Site I in subdomain IIA. One of these confor-
mations includes hydrogen-bonding interactions involving the
ketone moiety of 2a (Fig. 11(a)). Because these interactions
would preclude the formation of the tautomeric excited state
form of 2a, which is observed by uorescence, the other
conformation (Fig. 11(b)) is more likely. In this binding mode,
the hydroxyl oxygen atom, which would be deprotonated in the
tautomeric form, is stabilized by the presence of multiple
hydrogen bonding interactions.
Human serum albumin (HSA) contains only a single trypto-
phan residue near Site I. The binding properties for 2a to HSA
are similar to that observed for BSA, with a single molecule
binding with a binding constant of 3.0  103 M1 (Fig. S3(a–
c)†). Warfarin and ibuprofen experiments with 2a produced
a less pronounced effect relative to those observed for BSA
(Fig. S5(a) and (b)†), with a modest affect on binding of 2a only
being observed in the presence of warfarin. Overall, these
combined results strongly suggest that serum albumin proteins
bind 2a at Site I.
The binding properties of the O-benzoylsalicylate CO release
product 3a with BSA were also briey examined. As shown in
Fig. 12(a), this molecule also quenches the intrinsic uores-
cence of the protein. A modied Stern–Volmer analysis
(Fig. 12(c)) revealed that the binding affinity of 3a to BSA is
signicantly higher (Ka 107 M1) than that of 2a. Two mole-
cules of 3a bind to BSA. Competitive binding studies performed
using warfarin and ibuprofen (Fig. S6†) show signicant
changes in the binding constant for 3a in the presence of both
of these site markers. Docking of 3a with BSA resulted in the
identication of two binding sites, with the rst being Site I in
subdomain IIA and the second being a hydrophobic pocket in
subdomain IB. As shown in Fig. 13, binding for O-benzoylsali-
cylate derivative in Site I, which is likely the higher affinity
binding site, involves hydrogen-bonding interactions with two
nearby residues (ARG-208, Glu-353). In subdomain IB, which is
a secondary binding site for several drugs including AZT,65,66 the
interactions appear to be exclusively hydrophobic. Overall, the
distinctly different serum albumin binding properties of 2a and
3a place these compounds near the bookends of the range of
many known drug molecules that exhibit binding constants of
104–107 M1 at Site I in HSA.65
Our studies with [(bpy)Zn(2a)]ClO4 (4) demonstrate that
Zn2+ will form coordination complexes with the anion 2a. To
examine the effect of metal ions on the protein binding prop-
erties of 2a in aqueous buffer, titrations of solutions of BSA (1.4
mM) containing 150 mM Mn+ (Mn+ ¼ Mg2+, Ca2+, and Zn2+) with
2a were performed. As shown in Table 1, the presence of Zn2+
Fig. 11 Views of the binding of 2a to BSA near Site I in subdomain IIA.
Both conformations have similar energies.
Fig. 12 (a) Fluorescence emission of spectrum of BSA (1.4 mM) in
presence of various concentrations of 3a in TRIS buffer at pH¼ 7.4; T¼
298 K, lex ¼ 282 nm. [3a] ¼ 0, 1.4, 2.8, 5.6, 8.4, 11.2, 16.8, and 22.4 mM.
(b) Stern–Volmer plot of data for titration of BSA with 3a. (c) Modified
Stern–Volmer plot of data for titration of BSA with 3a.
































































































decreased the binding affinity of 2a for BSA to a value similar to
that observed for the zinc complex [(bpy)Zn(2a)]ClO4 (4)
(Table 1).
CO release reactivity
With an understanding of the solution properties of 2a under
a variety of aqueous conditions, we next examined the efficiency
of the visible light-induced CO release reaction (Scheme 1) under
the conditions listed in Table 2. The quantum yields for CO
release from 2a/2a ranges from 0.006 to 0.010, with binding of
2a to BSA producing a 10-fold lower quantum yield than that
found for the free molecule in 1 : 1 DMSO : buffer or CH3CN
solutions. Thus the reaction quantum yields found for 2a do not
change appreciably as a function of solvent. This is similar to the
quantum yields found for CO release from a Zn(II) 3-hydroxy-
avone complex wherein a change of solvent from CH3CN to
H2O : DMSO (1 : 1) resulted in only a two-fold change in reaction
quantum yield.67 For 2a the presence of Zn2+ in the form of the
[(bpy)Zn(2a)]ClO4 (4) complex produces a slightly higher
quantum yield (0.017(1)). We note that the quantum yields for
CO release obtained for 2a under all of these conditions are at
least ve-fold greater than those of the BODIPY derivatives 1a
and 1b under aerobic conditions.39
Discussion and conclusions
The development of carbon monoxide releasing molecules
(CORMs) for therapeutic applications is an area of signicant
current interest.2–8,15,16 While the majority of CORMs evaluated to
date are based on a metal carbonyl moiety as the CO release unit,
challenges regarding incorporation of drug-like structural
components, combined with concerns about the possible side
reactivity and toxicity of such structures in therapeutic applica-
tions, have hampered further development. Metal-free CO-
releasing molecules, particularly those that can be controlled in
terms of the timing and location of CO release, are attractive as
such moieties are likely to be more amenable to standard
medicinal chemistry approaches.4 In this regard, CO-releasing
organic molecules that can be triggered by visible light are of
particular current interest. Two novel metal-free, visible light-
induced CO release structural motifs have been recently re-
ported. These are based on BODIPY (1a/1b)39 and extended
avonol (2a–d)42-type structural motifs. Both types of compounds
offer attractive features, including low-to-medium toxicity and
strong uorescent emission features that enable tracking in
a biological environment. An additional advantage of the BODIPY-
based compounds is the structural tunability that enables the use
of light of >700 nm to induce CO release. Weaknesses of the
BODIPYmotif include the requirement of anaerobic conditions to
achieve quantitative CO release and the lack of full characteriza-
tion and toxicity evaluation of the CO release products. The
extended avonol motif offers several notable features that are
desirable toward the further development of visible light induced
CO release compounds. We previously reported the structural
tunability of the avonolmotif in 2a–d that enablesmodulation of
the wavelength of light that can be used to induce CO release as
well as tune the quantum yield for this reaction.42 We discovered
that one derivative (2d) offers the opportunity to access anaerobic
CO release reactivity. Another distinct advantage of the framework
in 2a is the ease of synthesis, which involves a one-pot reaction
from commercially available starting materials.
In this contribution, we outline details of the solution
properties of 2a in aqueous buffer environments at physiolog-
ical pH (7.4) and in the presence of charged or biologically
relevant molecules. Our results indicate that 2a can undergo
partial ionization to 2a under certain conditions (e.g., in PBS
buffer or in the presence of a cationic surfactant). We have
found that the presence of Zn2+ will enhance the quantum yield
for CO release from 2a. Overall this knowledge is important with
regard to using 2a in biological environments.
As we have described herein, compound 2a is the most
reactive metal-free photoCORM motif reported to date under
a variety of conditions. The ease of synthesis and structural
modication of the extended avonol framework of 2a, coupled
with the reliability of the molecule in terms of visible light
induced CO release reactivity under aqueous conditions, makes
it especially well-suited for the further development of a family
of CO-releasing molecules with modications to enhance bio-
logical properties, functionality, and targeting. Such efforts are
currently underway in our laboratory.
Acknowledgements
We thank the US National Science Foundation (CHE-1301092 to
LMB; CHE-1429195 for Bruker Avance III HD Ascend-500 spec-
trometer) for funding.
Fig. 13 View of the binding of 3a to BSA in Site I of subdomain IIA.
Table 2 Quantum yields for visible light (l ¼ 419 nm) induced CO
release from 2a under various conditions under air
Conditions (pH ¼ 7.4) Quantum yield
CH3CN 0.007(3)
1 : 1 DMSO : TRIS 0.006(3)
1 : 1 DMSO : PBS 0.010(3)
4% DMSO : PBS + CTAB 0.0063(1)
BSA (40 eq.) in 3.3% DMSO : TRIS 0.0006(1)
[(bpy)Zn(2a)]ClO4 in 1 : 1 DMSO : H2O 0.017(1)
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B. K. Krämer, M. Hafner, S. Amslinger, H. G. Schmalz and
B. A. Yard, Free Radical Biol. Med., 2013, 65, 78.
28 S. Romanski, B. Kraus, M. Guttentag, W. Schlundt,
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